3D bioprinting vasculatures is perhaps the holy grail of the next industrial revolution in healthcare. Biofabrication and bioprinting of any viable three-dimensional tissue will not be successful unless the vascularization challenge has been solved. Many organizations and talents around the world are actively tackling this challenge, but where are we exactly? Hear the latest perspectives, updates, and revelations from a group of technical and industrial superstars.
Please see FAQ about 3DHEALS here. This event also serves to network freely and to connect Pitch3D start-ups and investors during the breakout session, you can apply here. The on-demand recording will also be available here after the event.
Check back soon for precise event timing!
Apply to speak or sponsor event: firstname.lastname@example.org
Taci Pereira is Vice President and General Manager, Bioprinting at 3D Systems, where she leads the development and commercialization of research tools for 3D bioprinting applications. Taci was previously the Chief Scientific Officer at Allevi, a startup 3D Systems acquired in 2021. Taci leads the 3D bioprinting working group for the Regenerative Medicine Manufacturing Society, a professional society dedicated to advancing manufacturing solutions for the field of regenerative medicine. Originally from Curitiba, Brazil , She holds a Bachelor of Science in Bioengineering from Harvard University, where she worked at the Wyss Institute for Biologically Inspired Engineering. Taci’s research at the Mooney Laboratory for Cell and Tissue Engineering (Wyss) focused on biomaterials for cancer immunotherapy, under the advisory of David Mooney, Ph.D.
Ibrahim Tarik Ozbolat is an Associate Professor of Engineering Science and Mechanics, Biomedical Engineering and Neurosurgery, and a member of the Huck Institutes of the Life Sciences at Penn State University. Dr. Ozbolat’s main area of research is in the field of 3D Bioprinting. He has been working on several aspects of bioprinting such as bioprinting processes, bioink materials, bioprinters and post-bioprinting tissue maturation for manufacturing of more than a dozen tissues and organs. Dr. Ozbolat is a leading scientist with over 150 publications, including a sole-authored book in his domain. Due to his notable contributions to the field of bioprinting, he has received several prestigious international and national awards including 2014 NSF CAREER Award, 2014 SME Outstanding Young Manufacturing Engineer Award, 2014 ASME Chao and Trigger Young Manufacturing Engineer Award, 2014 ASME Tau Pi Sigma Gold Medal, 2015 IIE Dr. Hamid K. Eldin Outstanding Early Career Industrial Engineer in Academia Award, 2015 International Outstanding Young Researcher in Freeform and Additive Manufacturing Award and 2017 Hartz Family Career Development Professorship at Penn State.
Marc Thurner is a visionary, entrepreneur and pioneer in biofabrication technologies, currently acting as Chief Executive Officer at mimiX biotherapeutics Ltd. He pioneered the field of 3D bioprinting with his former creation regenHU Ltd, today recognized as an industry leader in the development of innovative biomedical solutions. A micro technology engineer Graduate, Marc started his professional career as an R&D engineer, managing international projects for the high precision automation industry. His avant-gardiste view that the future of regenerative medicine lay in converging engineering and biomedical science, brought him to found regenHU Ltd in 2007 and mimiX biotherapeutics Ltd in 2020. In 2012 Marc created the regenHU spin-off Vivos Dental Ltd, specialized in innovative 3D-printed bone grafting solutions for oral bone augmentation. Being an industry transformation leader, mimiX biotherapeutics develops leading-edge solutions in biotechnology and tissue engineering that enable scientific and clinical breakthroughs. The Swiss-based company collaborates with a global network of scientific innovators and industry players and leads the development of biomedical products for regenerative medicine and drug discovery. Marc Thurner and the mimiX biotherapeutics team are passionate about addressing the current and next generation biotechnology challenges to help the progress of Life Sciences.
During my PhD, I worked on the role of PI3Ks on the platelet functions and thrombus formation using in particular microfluidic/videomicroscopy technics. My postdoc research was focused on the development of 3D bone marrow models for the study of thrombocytopenia, developping bioreactor for ex-vivo platelet production and drug testing purposes using silk fibroin biomaterial and 3D bioprinting approach. I am now Senior Field Application Scientist at CELLINK, a BICO company promoting how our amazing bioconvergence technologies contribute to the future of biomedical research.
William is a Ph.D. candidate within the School of Biomedical Engineering at the University of Melbourne. He obtained a certificate 3 in business management and an honors degree in medical biotechnology from the University of New South Wales where he first entered research focusing on biomaterials, stem cells, and nanofabrication processes for tissue regeneration. Currently, his Ph.D. investigates the use of acoustic micromanipulation and 3D bioprinting as tools to pattern and define the cellular microenvironment. William has held roles as a research assistant and a business development consultant, where he currently serves as a community and events manager for 3D Heals and an organizing committee member for the Australian Bioprinting Workshop.
Now on Demand:
Thanks to our event sponsor: